Navigation Links
Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team

WAYNE, Pa., May 7 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that Professor Hanna Nohynek, M.D., Ph.D. has been appointed Head Consultant of Encorium's clinical vaccine research team.

Dr. Nohynek has an impressive track record in global clinical vaccine development. She is currently a Member of the Global Advisory Committee on Vaccine Safety of the World Health Organization. She has recently served as an EU Commission appointed member of the Health Security Working Group on platform for development of counter bioterrorism medicinal products. She has also recently been the Scientific Coordinator and/or co-investigator in seven Phase II trials on a number of vaccines (Haemophilus influenzae type b, meningococcal conjugate, and pneumococcal conjugate among infants, and pneumococcal polysaccharide among pregnant mothers and infants), as well as a large Phase III pneumococcal conjugate vaccine trial conducted in the Philippines with approximately 12,000 patients.

Dr. David Ginsberg, Encorium Group's Chief Executive Officer, stated, "We are extremely pleased that Dr. Nohynek has agreed to join Encorium as Head Consultant of our clinical vaccine research team. She brings a truly global experience to our team and we look forward to working with her."

Dr. Kai E. Lindevall, Executive Chairman of Encorium Group, added, "Dr. Nohynek is one of the leading experts in the field of clinical vaccine development. She will substantially strengthen our vaccine franchise and contribute to our ability to conduct global vaccine trials. Her experience conducting vaccine clinical trials in Asia-Pacific, in particular, should prove very valuable for our clients."

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions regarding future expectations. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i) the risk that we may not have sufficient funds to operate our business; (ii)our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) our ability to successfully integrate the business of Remedium Oy, which we acquired on November 1, 2006; (xiv) the performance of the combined businesses to operate successfully and generate growth; and (xv) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Form 10-K for a more complete discussion of factors which could cause our actual results and financial position to change.

You should not place any undue reliance on these forward-looking statements which speak only as of the date of this press release. Additional information concerning factors that might affect our business or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2008 and other periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from Encorium Group's investor relations department.

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference
2. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes Jr. Award
3. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes, Jr. Award
4. Professor K. C. Nicolaou Speaks at WuXi AppTec
5. Nyenrode Honorary Doctorate for Professor Michael E. Porter
6. Thin films research lands engineering professor Air Force Young Investigator Award
7. Gift Aids Professor's Research into Vein Treatment
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. UCF professor develops vaccine to protect against black plague bioterror attack
10. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
11. Stuart Parkin first distinguished professor at Eindhoven University of Technology
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):